Cue Health Inc.
HLTHDelisted- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001628945
Cue Health Inc. was delisted in 2024; its insiders filed their last Form 4 on Aug 27, 2024; 57 institutions reported holding it in 13F filings for Q1 2024, worth $10.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 57
- Q1 2024, −5 vs. previous quarter
- 13F value
- $10.5M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Superinvestors holding HLTH, Q1 2024
No superinvestor reported holding HLTH at the end of Q1 2024.
Latest insider trades
Open-market purchases and sales by Cue Health Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2024 (view filing)8:07 PM ET | Aug 23 | 4 days | Tarsadia Capital, LLC and 8 others10% Owner | SSaleCommon stock, par value $0.00001 per share ("Common Stock") | −10.7M | $0.0001 | −$1.07K | −100.0%0 after | |
| Aug 27, 2024 (view filing)8:07 PM ET | Aug 23-27 | 4 days | Tarsadia Capital, LLC and 8 others10% Owner | SSale | −7.62M | $0.00 | $0 | −100.0%0 after | 3 lots |
| Dec 9, 2022 (view filing)8:32 PM ET | Dec 8 | 1 day | Sever ClintChief Product Officer | SSale | −29.3K | $3.02 | −$88.3K | −0.7%3.94M after | |
| Dec 7, 2022 (view filing)9:11 PM ET | Dec 6-7 | 1 day | Sever ClintChief Product Officer | SSale | −50.8K | $3.06 | −$155.7K | −1.3%3.94M after | 2 lots |
| Dec 1, 2022 (view filing)7:31 PM ET | Nov 30 | 1 day | Sever ClintChief Product Officer | SSale | −22.7K | $3.11 | −$70.7K | −0.6%3.95M after | |
| Nov 25, 2022 (view filing)6:07 PM ET | Nov 22-25 | 3 days | Sever ClintChief Product Officer | SSale | −57.3K | $2.54 | −$145.5K | −1.4%3.95M after | 3 lots |
| Nov 10, 2022 (view filing)9:03 PM ET | Nov 8-10 | 2 days | Sever ClintChief Product Officer | SSale | −80.0K | $3.83 | −$306.1K | −2.0%3.95M after | 3 lots |
| Oct 27, 2022 (view filing)9:19 PM ET | Oct 25-27 | 2 days | Sever ClintChief Product Officer | SSale | −80.0K | $3.61 | −$289.0K | −2.0%3.95M after | 3 lots |
| Oct 13, 2022 (view filing)8:03 PM ET | Oct 11-13 | 2 days | Sever ClintChief Product Officer | SSale | −80.0K | $3.29 | −$262.9K | −2.0%3.95M after | 3 lots |
| Oct 3, 2022 (view filing)8:33 PM ET | Sep 30 | 3 days | Sever ClintChief Product Officer | SSale | −7.37K | $3.03 | −$22.3K | −0.2%3.95M after |
Top 10 13F holders, Q1 2024
The largest institutional positions in Cue Health Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tarsadia Capital, LLC | 10,684,791 | $2.02M | 6.24% | 00.0% | Unchanged |
| Oakmont Corp | 9,595,348 | $1.81M | 0.44% | 00.0% | Unchanged |
| Decheng Capital LLC | 8,980,909 | $1.70M | 0.23% | 00.0% | Unchanged |
| Madrone Advisors, LLC | 7,078,566 | $1.34M | 0.18% | 00.0% | Unchanged |
| Vanguard Group Inc | 3,884,285 | $732.6K | 0.00% | 00.0% | Unchanged |
| Temasek Holdings (Private) Ltd | 3,125,000 | $589.4K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 2,850,551 | $537.6K | 0.00% | −1,076,339−27.4% | Reduced |
| Mirae Asset Global Investments Co., Ltd. | 185,557 | $330.3K | 0.00% | +185,557 | New |
| BlackRock Inc. | 1,561,931 | $294.6K | 0.00% | −10,654−0.7% | Reduced |
| Geode Capital Management, LLC | 1,097,716 | $207.1K | 0.00% | +58,852+5.7% | Added |